Strategies to maintain remission in high risk CD19 lymphoid malignancies

Share :
Published: 19 Jun 2013
Views: 6167
Dr Partow Kebriaei - MD Anderson Cancer Center, Houston, USA

Dr Partow Kebriaei talks to ecancer at the 18th EHA Congress about her abstract on artificial antigen presenting cells that generate T cells expressing CD19-specific chimeric antigen receptor in order to prevent relapse in lymphoid malignancies.